EffRx Pharmaceuticals Statement on COVID-19

The globe has literally gone into quarantine due to the COVID-19 outbreak. This is an unprecedented crisis situation in terms of breadth and scale, from a global health, social and economic standpoint. While committed to keep our core activities unaffected, EffRx has implemented measures aimed at guaranteeing business operation continuity, with particular focus on the

Learn More

Meet the EffRx Team at the 25th Annual BIO-Europe International Conference from November 11-13, 2019 in Hamburg

EffRx will be attending Europe’s largest life science partnering conference, BIO-Europe, which offers countless opportunities to engage with global life science partners. This year´s BIO-Europe partnering event will again draw over 4,000 industry attendees from over 60 countries, representing more than 2,000 companies for three days of high-level networking. To set up a meeting, please

Learn More

EffRx to Attend the Medical Meeting: Bisphosphonates2019 – Celebrating 50 Years from 15-17th July 2019 in Sheffield, UK

EffRx Pharmaceuticals SA is proud to announce that it will attend the upcoming medical meeting bisphosphonates2019 – Celebrating 50 years, taking place 15-17th of July 2019 in Sheffield, UK. The year 2019 marks 50 years since the first publication on the biological effects of the bisphosphonates. The meeting which focuses 100% on bisphosphonates will review

Learn More

EffRx Pharmaceuticals Signs Exclusive License Agreement with Pharmaxis for the Registration and Commercialization of Bronchitol® in Switzerland

FREIENBACH, Switzerland (BUSINESS WIRE) – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has entered into an exclusive license agreement with Pharmaxis Ltd, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol® (mannitol) for cystic fibrosis in Switzerland. Under

Learn More

Binosto® Booth a Success at the WCO-IOF-ESCEO Congress in Paris

EffRx would like to thank everyone who helped make the Binosto® booth a success at the 19th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. With more than 4,000  delegates, the WCO-IOF-ESCEO Congress was an optimal platform for showcasing our lead product Binosto®.

Learn More

EffRx to Showcase Binosto® at the WCO-IOF-ESCEO 2019 in Paris

FREIENBACH, Switzerland–(BUSINESS WIRE)– EffRx Pharmaceuticals SA is proud to announce that it will participate in the 19th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, taking place April 4-7, 2019 in Paris. The WCO-IOF-ESCEO Congress is the world’s leading clinical conference on bone, joint and muscle health and therefore the ideal venue

Learn More

EffRx Pharmaceuticals | EffRx